Recent TELO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 01:15:16 PM
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer • ACCESS Newswire • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:00:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/17/2026 09:28:20 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 02/19/2026 10:16:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/19/2026 10:12:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:00:48 PM
- Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models • ACCESS Newswire • 02/17/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging • ACCESS Newswire • 02/05/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 12:30:43 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 01/23/2026 10:04:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 01:00:54 PM
- Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models • ACCESS Newswire • 01/05/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development • ACCESS Newswire • 12/18/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2025 09:01:45 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 11/28/2025 09:59:00 PM
- Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells • ACCESS Newswire • 11/25/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2025 09:01:40 PM
- Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells • ACCESS Newswire • 11/21/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 10:15:27 PM
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 11/20/2025 09:16:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:01:58 PM
- Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line • ACCESS Newswire • 11/12/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:00:56 PM
